Humoral responses to SARS-CoV-2 vaccination in MM and WM
| Vaccine responses . | Cohort 1, MM (n = 93) . | Cohort 2, WM . | |||
|---|---|---|---|---|---|
| All patients (n = 48) . | 2A (n = 10) . | 2B (n = 21) . | 2C (n = 17) . | ||
| 28 days after primary vaccination series | |||||
| EIR, n (%) | 44/93 (47) | 12/48 (25) | 6/10 (60) | 2/21 (10) | 4/17 (24) |
| Positive Ab titer, n (%) | 87/93 (94) | 31/48 (65) | 9/10 (90) | 12/21 (57) | 10/17 (59) |
| Median Ab titer (range), U/mL | 188.0 (0-4 161) | 2.2 (0-2 500) | 282.3 (0-2 500) | 0.8 (0-2 500) | 0.6 (0-2 500) |
| After first booster | |||||
| EIR, n (%) | 66/79 (84) | 25/42 (60) | 7/10 (70) | 12/19 (63) | 6/13 (46) |
| Positive Ab titer, n (%) | 79/79 (100) | 31/42 (74) | 9/10 (90) | 14/19 (74) | 8/13 (62) |
| Median Ab titer (range), U/mL | 5 130 (3.2-25 000) | 998.5 (0-25 000) | 2 500 (0-25 000) | 1 215 (0-12 500) | 9.1 (0-2 500) |
| After second booster | |||||
| EIR, n (%) | 30/33 (91) | 16/18 (89) | 4/4 (100) | 6/7 (86) | 6/7 (86) |
| Positive Ab titer, n (%) | 33/33 (100) | 17/18 (94) | 5/5 (100) | 6/7 (86) | 7/7 (100) |
| Median Ab titer (range), U/mL | 8 169 (52.2-25 000) | 3 379 (0-12 500) | 5 829 (2 996-12 500) | 2 506 (0-7 996) | 5 731 (58.3-12 500) |
| 12 months after primary vaccination series ± booster(s) | |||||
| EIR, n (%) | 68/80 (85) | 33/40 (83) | 8/10 (80) | 14/17 (82) | 11/13 (85) |
| Positive Ab titer, n (%) | 80/80 (100) | 40/40 (100) | 10/10 (100) | 17/17 (100) | 13/13 (100) |
| Median Ab titer (range), U/mL | 3 955 (3.6-25 000) | 2 063 (0.4-25 000) | 3 086 (11.2-25 000) | 1 843 (0.4-10 908) | 3 414 (0.8-12 500) |
| Vaccine responses . | Cohort 1, MM (n = 93) . | Cohort 2, WM . | |||
|---|---|---|---|---|---|
| All patients (n = 48) . | 2A (n = 10) . | 2B (n = 21) . | 2C (n = 17) . | ||
| 28 days after primary vaccination series | |||||
| EIR, n (%) | 44/93 (47) | 12/48 (25) | 6/10 (60) | 2/21 (10) | 4/17 (24) |
| Positive Ab titer, n (%) | 87/93 (94) | 31/48 (65) | 9/10 (90) | 12/21 (57) | 10/17 (59) |
| Median Ab titer (range), U/mL | 188.0 (0-4 161) | 2.2 (0-2 500) | 282.3 (0-2 500) | 0.8 (0-2 500) | 0.6 (0-2 500) |
| After first booster | |||||
| EIR, n (%) | 66/79 (84) | 25/42 (60) | 7/10 (70) | 12/19 (63) | 6/13 (46) |
| Positive Ab titer, n (%) | 79/79 (100) | 31/42 (74) | 9/10 (90) | 14/19 (74) | 8/13 (62) |
| Median Ab titer (range), U/mL | 5 130 (3.2-25 000) | 998.5 (0-25 000) | 2 500 (0-25 000) | 1 215 (0-12 500) | 9.1 (0-2 500) |
| After second booster | |||||
| EIR, n (%) | 30/33 (91) | 16/18 (89) | 4/4 (100) | 6/7 (86) | 6/7 (86) |
| Positive Ab titer, n (%) | 33/33 (100) | 17/18 (94) | 5/5 (100) | 6/7 (86) | 7/7 (100) |
| Median Ab titer (range), U/mL | 8 169 (52.2-25 000) | 3 379 (0-12 500) | 5 829 (2 996-12 500) | 2 506 (0-7 996) | 5 731 (58.3-12 500) |
| 12 months after primary vaccination series ± booster(s) | |||||
| EIR, n (%) | 68/80 (85) | 33/40 (83) | 8/10 (80) | 14/17 (82) | 11/13 (85) |
| Positive Ab titer, n (%) | 80/80 (100) | 40/40 (100) | 10/10 (100) | 17/17 (100) | 13/13 (100) |
| Median Ab titer (range), U/mL | 3 955 (3.6-25 000) | 2 063 (0.4-25 000) | 3 086 (11.2-25 000) | 1 843 (0.4-10 908) | 3 414 (0.8-12 500) |